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Abstract
Background: It is widely assumed that apoptosis of eosinophils is a central component of resolution of allergic airway 
disease. However, this has not been demonstrated in human allergic airways in vivo. Based on animal in vivo 
observations we hypothesised that steroid-induced resolution of human airway eosinophilic inflammation involves 
inhibition of CCL5 (RANTES), a CC-chemokine regulating eosinophil and lymphocyte traffic, and elimination of 
eosinophils without evident occurrence of apoptotic eosinophils in the diseased tissue.
Objective: To determine mucosal eosinophilia, apoptotic eosinophils, general cell apoptosis and cell proliferation, and 
expression of CCL5 and CCL11 (eotaxin) in human allergic airway tissues in vivo at resolution of established 
symptomatic eosinophilic inflammation.
Methods: Twenty-one patients with intermittent (birch and/or grass) allergic rhinitis received daily nasal allergen 
challenges for two seven days' periods separated by more than two weeks washout. Five days into these "artificial 
pollen seasons", nasal treatment with budesonide was instituted and continued for six days in a double blinded, 
randomized, placebo-controlled, and crossover design. This report is a parallel group comparison of nasal biopsy 
histochemistry data obtained on the final day of the second treatment period.
Results: Treatments were instituted when clinical rhinitis symptoms had been established. Compared to placebo, 
budesonide reduced tissue eosinophilia, and subepithelial more than epithelial eosinophilia. Steroid treatment also 
attenuated tissue expression of CCL5, but CCL11 was not reduced. General tissue cell apoptosis and epithelial cell 
proliferation were reduced by budesonide. However, apoptotic eosinophils were not detected in any biopsies, 
irrespective of treatment.
Conclusions: Inhibition of CCL5-dependent recruitment of cells to diseased airway tissue, and reduced cell 
proliferation, reduced general cell apoptosis, but not increased eosinophil apoptosis, are involved in early phase 
steroid-induced resolution of human allergic rhinitis.
Background
Airway tissue signs of established inflammation in
asthma and allergic rhinitis include increased mucosal
tissue cell turnover, eosinophilia, and increased
chemokine production. Institution of steroid treatment
eventually reduces both symptoms and eosinophilic
inflammation in allergic airways diseases [1]. However,
early resolution effects in vivo of this mainstay class of
airway drugs are incompletely understood.
In recent years, based largely on observations in vitro,
the view that established airway tissue eosinophilia is
resolved through steroid-induced apoptosis of these cells
has been widely accepted [2-5]. Unexpectedly, therefore,
we and others observed that steroid-treatment resolved
established airway-pulmonary eosinophilic inflammation
in murine in vivo models without inducing any detectable
apoptosis of tissue eosinophils [6-8]. At neither spontane-
ous nor steroid-induced resolution were apoptotic
eosinophils seen in the tissues in vivo [7,8]. Although
these data were at variance with predictions made from
in vitro experiments they were compatible with publi-
cised human and animal in vivo-information in the field
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of interest [9]. New data also emerged demonstrating that
airway tissue eosinophils could efficiently and non-injuri-
ously be eliminated by extra-apoptotic routes [7,9,10]. It
is of note that the previous studies had not examined
human diseased airways during steroid-induced resolu-
tion of allergic inflammation. This aspect is essential
because at the early phase of such resolving tissue eosino-
philia the chance of detecting apoptotic eosinophils
would be the greatest.
Studies involving allergic animals and humans demon-
strate broad anti-inflammatory airway effects when ste-
roids are given as prophylactic treatment prior to allergen
exposure [8,11]. By contrast, observations in animals
indicate that steroids given to airways with already estab-
lished allergic inflammation and remodelling may not
exhibit the same wide range of early effects [8,12]. Pro-
phylactic administration of a steroid thus inhibited aller-
gen challenge-induced up-regulation of CCL11 (eotaxin)
and CCL5 (RANTES) along with attenuation of several
other CC-chemokines in mouse lungs [8]. However, using
the same animal model and instituting the same steroid
treatment after the allergic eosinophilic inflammation
had been established, merely one lung tissue chemokine,
CCL5, was significantly inhibited [8]. This latter effect
was associated with steroid-induced resolution of the
eosinophilic inflammation. Similar to several other
eosinophil chemo-attractants, CCL5, a key regulator of
airway eosinophils and lymphocytes, has been demon-
strated in biopsies and lavage fluids obtained from
human airways in allergic disease [13-17]. Supporting the
possibility that an anti-CCL5 action is involved in thera-
peutic effects of steroids, Castro et al. further observed
that CCL5 became significantly increased in asthmatic
airway tissues along with worsening of the disease evoked
by stopping steroid treatment [17]. However, it is not
known whether early steroid-induced resolution of air-
way allergic inflammation involves any specific reduction
of CCL5 in the diseased human tissues.
The human nose provides opportunities for the study
of inflammatory processes germane to the respiratory
tract mucosa [18]. Using a validated repeat allergen chal-
lenge-model closely mimicking seasonal allergic rhinitis
[19,20], we have here studied early phase resolution of
airway eosinophilic inflammation with and without ste-
roid treatment. The features of this model include estab-
lishment of consistent around-the-clock disease
symptoms along with eosinophilic inflammatory pro-
cesses. In the present study, we report on tissue indices of
inflammation assessed in biopsies obtained at one point
in time (parallel group analysis) at the end of a crossover
exploratory study of early resolution of symptomatic
rhinitis. We have focused on epithelial and subepithelial
eosinophilia, expression of CCL11 and CCL5, and occur-
rence of apoptotic and non-apoptotic eosinophils in the
human nasal mucosa with resolving tissue eosinophilia.
In addition, inflammation as reflected by mucosal cell
turnover indices has been examined.
Methods
Study design and ethical approval
Patients with seasonal (intermittent) allergic rhinitis were
subjected to daily nasal allergen challenges for two seven
days' periods outside the pollen season. Five days into the
"artificial pollen season" [19,20] nasal treatment with
budesonide was instituted in a double blinded, random-
ized, placebo-controlled, and crossover design and con-
tinued for six days. (Fig.1). Nasal symptoms were
monitored. On Study days 5, 6, 8, and 10 of each allergen
challenge series, nasal lavage was carried out. However,
the focus of the present report was on the analysis of
nasal biopsies obtained on the final day of the second
treatment period (Study day 10). This latter parallel-
group comparison involved ten patients on treatment
with budesonide and eleven patients on treatment with
placebo. The human study was in accordance with the
Helsinki Declaration, and ethical approval was obtained
by the Ethical Committee at Lund University Hospital
(reference number: LU504-01). All patients gave written
consent prior to participate in the study.
Patients
Twenty-one patients were recruited to the study (15
males and 6 females). The median age was 24 (range 20-
41). Inclusion criteria were a history of strictly intermit-
tent (birch and/or grass) allergic rhinitis for at least two
years, a positive skin-prick test to birch and/or grass pol-
len allergen, and a need for medical treatment at seasonal
allergen exposure. Exclusion criteria were asthma, a his-
tory of perennial (persistent) allergic rhinitis or a positive
skin prick test to perennial allergens, and other chronic
nasal disease or major nasal structural abnormalities. The
only permitted drug treatment was rescue medication
provided by the investigator (loratadine, 10 mg tablets,
Schering-Plough).
Allergen-challenge
In order to identify an individual, tolerable, yet symptom-
producing dose for the nasal allergen-challenge series, a
titration procedure was performed. Increasing doses of
birch or timothy pollen allergen were administrated at
10-min intervals using a spray-device delivering 100 μl
per actuation (Aquagen, ALK, Horsholm, Denmark). One
puff was sprayed into each nostril resulting in effective
doses of 100, 300, 1000, and 3000 Standard Quantity-
Units (SQ-U) per cavity. This scheme was followed until a
response of 5 sneezes or a score of 2 or more, on a scale
from 0 to 3, for either of the symptoms blockage or rhin-
orrhea. The dose that produced this effect was chosen for
the daily challenges.Uller et al. Respiratory Research 2010, 11:54
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Study drug
The subjects were treated with budesonide (AstraZeneca
R&D, Lund, Sweden) and placebo. An aqueous suspen-
sion of budesonide (1.28 mg/ml) was provided in glass
bottles fitted with mechanical spray-pump delivering 64
μg budesonide per actuation. Placebo was provided in
identical glass bottles and with identical spray pumps.
The subjects were given two actuations into each nostril
of either budesonide (total daily dose: 256 μg) or placebo
once daily for six days, starting on Study day 5 of the
allergen challenge series. The first dose of study drug/pla-
cebo was taken at the clinic under supervision of the
investigator and the subsequent doses were taken at
home every morning.
Symptoms and nasal lavage
During the study period, nasal symptoms were scored in
the morning (before intake of the drug), post challenge,
and in the evening. The score in the morning and evening
reflected the last 12 hours and was entered into a diary.
The symptoms blocked nose, runny nose, and sneezing/
itching were each scored on a 4-graded scale: 0 = no, 1 =
mild, 2 = moderate and 3 = severe symptoms. Symptom
scores for morning and evening recordings, respectively,
were added to a total nasal symptom score (TNSS, range
0-9). Nasal saline lavages were carried out on Study days
5, 6, 8, and 10 using a nasal pool-device [21]. On Study
days 5 and 6, these lavages were carried out before the
daily allergen challenge. In the present study, the volume
of the pool-fluid was 15 ml and the dwell time 5 min. The
samples were centrifuged (325g, 10 min, 4°C) and sam-
ples were obtained from the supernatant and frozen (-
30°C). CCL5 and CCL11 were measured with ELISAs
(R&D Systems, Minneapolis, MN).
Nasal biopsy
Two nasal biopsies were obtained from each patient at
the end of the second treatment period (Study day 10).
Topical anaesthesia and mucosal decongestion was
achieved by administration of tetracain (20 mg/ml) and
adrenalin (0.1 mg/ml) first by a spray-device and then by
a cotton swab. In addition, ten min later, a mixture of car-
bocain (10 mg/ml) and adrenalin (5 mg/ml) was injected
into the inferior nasal turbinate. Using a cutting forceps
with a 3 mm drilled out punch, a biopsy was taken from
the inferior turbinate about 5 mm from its anterior mar-
gin. The biopsies were directly frozen in TissueTek
(Sakura Finetek Europe, Zoeterwoude, The Netherlands)
and stored at -80ºC.
Histological analyses of nasal biopsies
Histochemical detection of eosinophils
Eosinophils were detected by histochemical visualisation
of cyanide-resistant eosinophil peroxidase as previously
described [7,22]. Eosinophils were identified by their dark
brown reaction product and quantified in the epithelial
lining and the lamina propria as numbers of eosinophils/
0.1 mm2 tissue area and eosinophils/mm2, respectively.
The whole biopsy was subjected to analysis in a blinded
manner.
Detection of apoptotic cells with the TUNEL-technique
Apoptosis was visualized using the in situ TUNEL-tech-
nique that we previously have validated in animal and
human airway tissues [7,22]. Cryosections (5-10 μm)
were directly fixated in 2% paraformaldehyde and then
pretreated with proteinase K (20 μg/ml) (Sigma, Stock-
holm, Sweden) for 15 min at room temperature. DNA
strand breaks obtained during apoptosis were detected by
enzymatic labelling of free DNA termini using an in situ
apoptosis kit (ApopTag fluorescein, Intergen, NY). Thy-
Figure 1 Scheme of allergen challenges, budesonide (corticosteroid, CS) treatment, and sampling representing the challenge/treatment 
series. The biopsies*, which are the focus of the present analysis, were obtained only on the final study day (Study day 10 of the second series of al-
lergen challenges).Uller et al. Respiratory Research 2010, 11:54
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mus from corticosteroid-treated rats was used as a posi-
tive control. No staining was evident in negative controls,
i.e., when the Tdt-enzyme was omitted. Slides were coun-
terstained with propidium iodide to reveal pyknotic
nuclei as well as the total number of cells. Apoptotic cell
nuclei were stained intensely green and quantified as total
apoptotic cells/mm2. Apoptotic eosinophils were defined
as both chromotrope 2R-positive and TUNEL-positive
cells exhibiting apoptotic morphology, i.e., small cells
with condensed nuclei.
Immunostaining for proliferating cells using light microscopy
Cryosections were incubated over night with a monoclo-
nal mouse anti human Ki-67 antibody (dilution 1:80,
clone Ki-S5, Dako, Glostrup, Denmark) and visualised by
a secondary goat anti-mouse FITC antibody (1:200, Jack-
son Immuno Research, West Grove, PA). Proliferating
epithelial cells were quantified as number of cells/0.1 mm
basement membrane.
Immunostaining for CCL5 and CCL11
Cryosections (5-10 μm) were directly fixated in ice-cold
2% formaldehyde and washed in EBSS buffer-saponin. A
biotinylated anti-human CCL5 antibody (2.5 μg/ml, BAF
278, R&D Systems, Abingdon, UK.) and a monoclonal
anti-human CCL11 antibody (5 μg/ml, MAB320, R&D
Systems, Abingdon, Systems, UK.) were used and stained
according to manufactures instructions. Haematoxylin
was used as background staining. Sections were exam-
ined with a standard light microscope (Bx-60, Olympus,
Tokyo, Japan) in a blinded manner and photomicro-
graphs were taken with a 10x objective and saved in
TIFF-format for analysis of Integrated Optical Density
(IOD) using the Image-Pro Plus 4.5 software (Media
Cybernetics, Silverspring, MD, USA) as previously
described [23]. Image-pro Plus software was used to cal-
culate stained area (μm2) and Integrated Optical Density
(IOD) (area x average density) for CCL5 and CCL11.
Statistics
Symptom scores, lavage fluid indices, and tissue indices
were considered non-parametrically distributed. Differ-
ences between groups receiving treatment with budes-
onide and placebo were examined using the Mann
Whitney U-test. P-values <0.05 was considered statisti-
cally significant. Paired analyses within each treatment
group were carried out using the Wilcoxon Signed Rank
test. Histology data is presented as mean ± SEM. Symp-
toms and lavage data in Table 1 are presented as median
and interquartile range.
Results
Allergen challenges
Thirteen patients received nasal challenges with timothy-
pollen allergen and 8 with birch-pollen allergen. The indi-
vidual dose-titration resulted in that 4, 3, and 6 subjects
received daily challenges with 100, 300, and 1000 SQ-U of
timothy allergen, respectively and 4, 2, 1, and 1 subjects
received 100, 300, 1000 and, 3000 SQ-U of birch allergen.
Rescue medication (loratadine) was used by patients in
both the placebo group (1 patient taking 4 tablets, 3
patients taking 1 tablet each) and budesonide group (2
patients taking 1 tablet each) during days 5- 8. Thus, no
antihistamine medication was taken during the last 48h
prior to sampling the biopsies.
Symptoms and lavage data
The challenges produced mild rhinitis symptoms: For
example, evening total nasal symptoms on Study day 4
(placebo and budesonide groups together prior to any
treatment had begun) were scored 1.7 compared with
evening symptoms on Study day 1 scored of 1.3. Budes-
onide reduced symptoms compared with placebo during
Study days 5-10, but these changes failed to reach statisti-
cal significance (paired analysis involving both treatment
periods, data not shown). At the time when the biopsies
were obtained, symptoms also did not differ between the
treatment groups (Table 1, parallel group analysis). Dur-
ing the present early phase of resolution lavage fluid lev-
els of CCL5 and CCL11 did not differ between
budesonide and placebo (paired analysis involving both
treatment periods, data not shown, and parallel group
analysis Study day 10, Table 1).
Airway tissue eosinophilia
In biopsies obtained from placebo-treated subjects, a
marked epithelial- and sub-epithelial eosinophilia
remained three days after cessation of the allergen-chal-
lenges (Fig. 2). In budesonide-treated individuals, the
total nasal tissue eosinophilia was reduced compared to
placebo treatment (Fig. 2A). The epithelial eosinophilia
was not significantly reduced by budesonide treatment
(Fig. 2B) but the eosinophilia beneath the epithelium was
significantly reduced (Fig. 2C).
Apoptosis and proliferation
The persisting allergic inflammation at placebo treatment
was associated with scattered occurrence of apoptotic
cells in the tissue and proliferating cells in the epithelium
(Fig. 3A and 3B). These indices of inflammatory stimu-
lus-induced local cell turnover were less pronounced in
the budesonide-treated group (Fig. 3A and 3B). Further-
more, apoptotic eosinophils were detected neither in the
placebo-group nor in the steroid-treated group.
Immunostaining of CCL5 and CCL11
In placebo-treated individuals, the intensity of CCL5
immunoreactivity was pronounced in the epithelium,
including the glandular epithelium, and in subepithelial
tissue (Fig. 3C and 4). In steroid-treated subjects, CCL5
immunoreactivity was less than in the placebo group (Fig.Uller et al. Respiratory Research 2010, 11:54
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3C and 4). By contrast, the CCL11 immunoreactivity was
of the same magnitude in placebo- and budesonide-
treated individuals (Fig. 3D).
Discussion
The present findings involving human airways indicate
that established allergic eosinophilic inflammation are
reduced by therapeutic steroid intervention already five
days after institution of treatment. We further demon-
strate a degree of selectivity in the steroid action in that
tissue CCL5 expression, but not CCL11, is reduced by
budesonide along with its attenuating effects on tissue
eosinophilia. In view of the established dogma [2-4] it
was most surprising that apoptotic eosinophils are not
detected in the airway tissues at ongoing, spontaneous or
drug-induced, resolution of the allergic airway inflamma-
tion. However, the present data obtained in a validated
model of human allergic rhinitis agree with previous
observations in vivo on early resolution of eosinophilic
inflammation in steroid-treated allergic animals.
Except for observations in animal models [8] there was
little prior information regarding early resolution of aller-
gic eosinophilic airways disease in vivo. This study thus
produced new data on the action of airway corticoster-
oids on eosinophilic inflammation in human airway tis-
sues in vivo. Exit of inflammatory cells and proteins into
the airway lumen may be a mode of elimination of these
players from the inflamed tissue [9]. During resolution,
increased inflammatory indices on the mucosal surface
may thus be associated with corresponding reductions of
the same indices in the diseased airway tissue. This com-
plicates the interpretation of lavage fluid data in this
study. Hence, the present focus was on airway tissue indi-
ces. Since the present model has a demonstrated consis-
tency at repeated studies of symptom development and
treatment effects of allergic rhinitis [19,20], we resorted
to one biopsy occasion only and parallel group analyses.
This was also done to avoid too much discomfort by the
biopsy procedures and prevent dropouts. An additional
consideration was that the institution of treatment had to
be optimal to pick up early phase resolution effects and at
the same time allow for a slow onset of action of the ste-
roid treatment. This is a field where helpful precedents
are scarce. As it turned out in this study, the tissue indices
of eosinophilic inflammation clearly remained present in
the placebo-treated subjects whereas biopsies obtained
from the steroid-treated group exhibited signs of a reso-
lution that was speeded up compared to the placebo
group of patients. At allergen exposure, individuals with
allergic asthma or allergic rhinitis may loose epithelial
cells and the ensuing epithelial restitution processes
involve increased cell proliferation [24]. It can further be
expected that ongoing inflammatory processes will
increase a general occurrence of cell apoptosis in the
affected airway tissue. The present finding of a reduced
number of apoptotic cells in airway tissues receiving ther-
apeutic steroids thus tallies with an overall anti-inflam-
matory efficacy of institution of the steroid treatment [7].
It has been widely assumed that apoptosis of airway tis-
sue eosinophils would be increased by corticosteroid
treatment [2-4]. Inducement of eosinophil apoptosis (fol-
lowed by a postulated efficient engulfment of the apop-
totic eosinophils) has thus been advocated as a major
pharmacological mechanism to bring about resolution of
airway eosinophilic inflammation [2-4]. By contrast, ani-
mal in vivo data have scarcely supported a role of apopto-
sis in the pharmacology of eosinophil elimination [6,8].
Thus, similar to the present findings, apoptotic eosino-
phils have not been unequivocally detected in steroid-
treated allergic airway tissues in vivo. Such negative data
are strengthened by the concomitant demonstration, as
in this study, that other types of apoptotic cells are
Table 1: Nasal symptom scores and cytokine levels in nasal lavage fluid.
Treatment
Placebo
(n = 11)
Budesonide
(n = 10)
p-value
Symptoms
- Morning TNSS 1.0 (1.0) 1.0 (2.0) 0.48
Nasal lavage
- CCL5 (pg/ml) 8.5 (9.0) 10.0 (27.6) 0.14
- CCL11 (pg/ml) 8.8 (4.5) 11.0 (13.1) 0.17
Median (IQR) total nasal symptom scores, and lavage fluid levels of CCL5 (RANTES) and CCL11 (eotaxin) on Study day 10 of the second 
treatment series, i.e., on the day the biopsies were obtained. Data were analysed using the Mann Whitney test (unpaired comparisons). No 
statistically significant differences were observed between the treatments.Uller et al. Respiratory Research 2010, 11:54
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observed in the allergic tissues. The present observations
are remarkable because we examined a phase where the
likelihood of eosinophil apoptosis should be the greatest
both in spontaneous and drug-induced resolution. Our
data may explain the scarcity of publicised reports on
eosinophil apoptosis in airway biopsies including the lack
of confirmation of a reported insignificant trend at ste-
roid-induced increased eosinophil apoptosis in asthma
[4]. Furthermore, the present observations question the
support that the current dogma is getting by reference to
reports on occurrence of apoptotic eosinophils in the
lumen of diseased airways [4]. Indeed, airway lumen find-
ings in this case have little relevance because apoptotic
cells in the airway tissue cannot migrate and can, there-
fore, not be revealed in airway lumen samples. It is at
present unclear if apoptosis of tissue eosinophils is a
desirable drug action since poor engulfment of these cells
may aggravate airway allergic inflammation [25]. A poor
engulfment  in vivo would further mean that apoptotic
eosinophils, when they occur in the tissue, should be
readily detected. Hence, we suggest that the present neg-
ative observations reflect true rarity of eosinophil apop-
tosis in spontaneously resolving as well as in
corticosteroid-treated human nasal allergic airway tis-
sues.
The present negative data on occurrence of apoptotic
eosinophils in the airway tissue at resolution of inflam-
mation support the possibility that airway tissue eosino-
phils can be swiftly and non-injuriously eliminated
through egression into the airway lumen [9]. In the lower
airways, egressed cells would be mixed with plasma exu-
dates and airway secretions and removed by the mucocil-
iary escalator. Removal of inflammatory cells on the
airway surface would be even more functional in the
nasal passages since final elimination, through swallow-
ing or blowing of the nose, is prompt and relatively
uncomplicated. Animal data suggest that corticosteroid
treatment does not prevent but may permit the egression
of eosinophils into the airway lumen [8]. In the present
study, it was considered impractical to collect all nasal
outputs during several days and nights to try and calcu-
late egression of eosinophils during the post challenge
period. However, the finding that subepithelial eosino-
philia tended to be reduced more than the epithelial
eosinophilia is compatible with the steroid treatment per-
mitting traffic of eosinophils towards the lumen in air-
ways with resolving eosinophilia.
The reduced eosinophilia in the corticosteroid group
would in part reflect reduced recruitment of these cells
during the period of steroid treatment. Although many
locally present eosinophil chemoattractants might con-
tribute, CCL5 and CCL11 have been pointed out as two
major chemokines involved in recruiting circulating
eosinophils to allergic airway tissues [26]. The present
Figure 2 Airway tissue eosinophilia in nasal biopsies during reso-
lution phase The total number of eosinophils in nasal biopsies was re-
duced after budesonide treatment (A). Eosinophils localised in the 
epithelial lining was not significantly reduced by budesonide treat-
ment (B). The reduction was more pronounced in the subepithelial tis-
sue (lamina propria; C). Data presented is mean ± SEM. (* Denotes p < 
0.05 and ** denotes p < 0.01).Uller et al. Respiratory Research 2010, 11:54
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demonstration of a reduced expression of CCL5, occur-
ring simultaneously to the reduced tissue eosinophilia,
suggests that CCL5, with its proposed roles in eosinophil
and lymphocyte recruitment, can be of special impor-
tance as pharmacological target. It is also possible that
disappearance of CCL5 from the tissue could have con-
tributed to migration of eosinophils into the airway
lumen [27]. Currently entertained molecular actions of
the anti-inflammatory steroids suggest that these drugs
exert non-selective inhibition of the generation of inflam-
matory chemokines [26]. Hence, the mechanism behind
the particular in vivo anti-CCL5 action of corticosteroids
in mouse [8] and human (this study) allergic airways
remains mechanistically challenging. Other selective
actions of steroids have been demonstrated previously
including observations that steroid treatment, despite its
potent anti-inflammatory effects, may spare leukocyte
and microvascular innate responses mobilised in relation
to epithelial repair [28] and microbial defence [29]. The
present inhibition of CCL5 and the association between
increase in airway CCL5 and deterioration of asthma at
stopping steroid treatment [17] support the view that this
protein may have a central role in maintaining inflamma-
tory processes in rhinitis and asthma.
We conclude that institution of nasal steroid treatment
in subjects with established symptoms of allergic rhinitis
Figure 3 Apoptotic and proliferating cells, and CCL5 and CCL11 staining in whole nasal biopsies at resolution of allergic inflammation. Oc-
currence of apoptotic cells in the tissue quantified by TUNEL-technique (A) and occurrence of proliferating cells in the epithelium stained using the 
proliferating marker Ki67 and quantified in the epithelium and expressed as cells/0.1 mm basement membrane length (B) of nasal biopsies. Average 
integrated Optical Density (IOD) times the calculated stained area (μm2) reflects the occurrence of CCL5 (C) and CCL11 (D) immunostaining in nasal 
biopsies. Data presented is mean ± SEM. (* Denotes p < 0.05.)Uller et al. Respiratory Research 2010, 11:54
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reduces tissue indices of allergic eosinophilic inflamma-
tion within five days. Our data support a role of inhibition
of CCL5-dependent cell recruitment, but challenge the
dogma that eosinophil apoptosis is involved in corticos-
teroid-induced resolution of allergic airway inflamma-
tion.
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